Membranous Nephropathy and Pulmonary Alveolar Proteinosis

Yamada, Hideaki; Miura, Naoto; Kitagawa, Wataru; Kashima, Yukari; Matsui, Seiko; Ozeki, Norio; Nishikawa, Kazuhiro; Imai, Hirokazu

doi:10.2169/internalmedicine.46.0129

Cited by 5 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result of post-translational modification, human α-enolase is a 47-kDa glycoprotein. Complementary DNA (cDNA) cloning and production of fusion proteins were described elsewhere [ 20 ]. Briefly, full-length and truncated cDNA encoding human α-enolase was amplified in polymerase chain reactions, and ligated to sequence encoding glutamine S-transferase (GST) (GE Healthcare Bio-Sciences Corp., Piscataway, NJ).…”

Section: Methodsmentioning

confidence: 99%

Circulating antibodies to α-enolase and phospholipase A2 receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy

et al. 2016

Self Cite

View full text Add to dashboard Cite

BackgroundPhospholipase A2 receptor (PLA2R) is recognized as a target antigen in primary membranous nephropathy (MN); Anti-α-enolase antibody in primary and secondary MN has been proposed, however, little is known about the potential contribution of α-enolase to the pathogenesis of MN.MethodsWe evaluated circulating antibodies to α-enolase by a dot blotting system and PLA2R by indirect immunofluorescence, and glomerular deposition of these proteins in 25 patients with primary MN, 20 patients with secondary MN, 44 patients with collagen disease or severe infection, 60 patients with nephritis (each ten patients of IgA nephropathy, focal segmental gloemrulosclerosis, minimal change nephrotic syndrome, membranoproliferative glomeurlonephritis, diabetic glomerulosclerosis, and tubulointerstitial nephritis) as disease control, and 20 healthy subjects.ResultsIn primary MN, 18 of 25 sera (72 %) showed anti-α-enolase antibody (IgG1 and IgG4, 11 pts; IgG4 alone, six pts; IgG1 alone, one pt). In secondary MN, 15 of 20 sera (75 %) contained anti-α-enolase antibody (IgG1 and IgG3, 13 pts; IgG3 alone, two pts). No circulating anti-α-enolase antibody was found in 44 collagen diseases or septic patients, 60 nephritis without MN, and 20 healthy subjects. Twelve of 25 sera (48 %) from patients with primary MN were positive for anti-PLA2R antibody, whereas all patients with secondary MN were negative. Eight of the 12 PLA2R-positive patients (67 %) with primary MN also had anti α-enolase antibody. Although PLA2R antigen was present in a subepithelial pattern in 10 of 19 (52 %) patients with primary MN, α-enolase was never detected in glomerular deposits in 19 and ten patients with primary and secondary MN, respectively.ConclusionsCirculating anti-α-enolase antibodies are highly present in both primary and secondary MN (about 70 %, respectively), while anti-PLA2R antibodies are specific for primary MN (48 %) with a prevalence apparently lower in the Japanese population than in Chinese and Caucasian populations. The absence of α-enolase from subepithelial immune deposits suggests that anti-α-enolase antibodies do not contribute directly to immune-deposit formation, although they may have other pathogenic effects. Electronic supplementary materialThe online version of this article (doi:10.1007/s10157-016-1235-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Methodsmentioning

confidence: 99%

Circulating antibodies to α-enolase and phospholipase A2 receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…They were classified as diffuse glomerulonephritis, membranous nephropathy, and mesangioproliferative glomerulonephritis [18]. The remaining cases involved a young adult who developed secondary amyloidosis in the setting of longstanding PAP, succumbing to his illness, [27] and 2 cases of membranous nephropathy [28, 29]. The first of these cases was a 38-year-old woman who presented with a pulmonary-renal syndrome comprising diffuse bilateral pulmonary infiltrates and the nephrotic syndrome, with biopsy-proven diagnoses of PAP and membranous nephropathy, and found to have an immunodeficiency syndrome, characterized by the absence of monocytes in the peripheral blood and bone marrow [28].…”

Section: Discussionmentioning

confidence: 99%

“…The patient eventually succumbed to her illness. The second case involved a 47-year-old woman presenting with nephrotic-range proteinuria, severe cough and fever, with evidence of bilateral pulmonary nodules and ground-glass opacities, and biopsy-proven diagnoses of PAP and membranous nephropathy [29]. While serum anti-GM-CSF antibodies could not be detected, the patient had circulating antibodies against alpha enolase, a cytoplasmic glycolytic enzyme expressed on the surface of monocytes and macrophages [30].…”

Section: Discussionmentioning

confidence: 99%

Potential association between membranous nephropathy and sargramostim therapy for pulmonary alveolar proteinosis

Sewaralthahab

Rennke

Sewaralthahab

et al. 2014

CNCS

View full text Add to dashboard Cite

We present the case of a 43-year-old woman with a diagnosis of pulmonary alveolar proteinosis, on chronic treatment with sargramostim, a recombinant granulocyte-macrophage colony-stimulating factor, who presented with the nephrotic syndrome secondary to biopsy-proven membranous nephropathy. We discuss potential underlying mechanisms, including speculated effects of sargramostim on mesangial cells and the kidney resident macrophages, and review the existing literature on the potential association between these two disorders.

show abstract

Section: Preparation Of α-Enolase Deletion Mutantsmentioning

confidence: 99%

Circulating Antipodocyte Antibodies in Membranous Nephropathy: Pathophysiologic and Clinical Relevance

Ronco

Dębiec

Imai

2013

American Journal of Kidney Diseases

Self Cite

View full text Add to dashboard Cite

HAL is a multidisciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

show abstract

Membranous Nephropathy and Pulmonary Alveolar Proteinosis

Abstract: Abstract

Cited by 5 publications

References 30 publications

Circulating antibodies to α-enolase and phospholipase A2 receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy

Circulating antibodies to α-enolase and phospholipase A2 receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy

Potential association between membranous nephropathy and sargramostim therapy for pulmonary alveolar proteinosis

Circulating Antipodocyte Antibodies in Membranous Nephropathy: Pathophysiologic and Clinical Relevance

Contact Info

Product

Resources

About